Literature DB >> 25644067

[Dermatomyositis-specific antibodies].

L Bodoki1, M Nagy-Vincze, Z Griger, K Dankó.   

Abstract

BACKGROUND: Idiopathic inflammatory myopathies are chronic systemic autoimmune diseases characterized by symmetrical proximal muscle weakness. The clinicopathological subdivision nowadays appears to be obsolete which is why the immunoserological classification has been developed.
OBJECTIVES: Dermatomyositis represents one the most important subsets of idiopathic inflammatory myopathy and dermatomyositis-specific autoantibodies play a significant role in this subset. The aim of this article was to present these autoantibodies with the help of the literature.
METHODS: This article presents the most important information about dermatomyositis including not only the classical anti-Mi-2 autoantibody but also the recently detected anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5 autoantibodies. The focus is on the frequency of these autoantibodies, the associated symptoms in adult and juvenile dermatomyositis cases and some special aspects from the literature.
RESULTS: All of the studies confirmed that these autoantibodies are particularly detectable in dermatomyositis. The results from the literature have recently shown that the frequency of the autoantibodies detected in juvenile cases is higher than the frequency of traditional autoantibodies (e.g. anti-Jo-1, anti-Mi-2 and anti-SRP).
CONCLUSION: It is useful to detect these autoantibodies in order to be able to make a better assessment of the clinical symptoms and prognosis during the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25644067     DOI: 10.1007/s00393-014-1524-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  35 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; O Decaux; S Dominique; E Diot; C Landron; P Roblot; S Jouneau; P Y Hatron; K P Tiev; O Vittecoq; D Noel; L Mouthon; J-F Menard; F Jouen
Journal:  Autoimmun Rev       Date:  2012-02-03       Impact factor: 9.754

3.  Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen.

Authors:  G J D Hengstman; W T M Vree Egberts; H P Seelig; I E Lundberg; H M Moutsopoulos; A Doria; M Mosca; J Vencovsky; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

4.  Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Authors:  Antonia Valenzuela; Lorinda Chung; Livia Casciola-Rosen; David Fiorentino
Journal:  JAMA Dermatol       Date:  2014-07       Impact factor: 10.282

5.  [PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].

Authors:  S Kim; E Genth; T Krieg; N Hunzelmann
Journal:  Z Rheumatol       Date:  2005-10       Impact factor: 1.372

6.  [Risk factors for cancer in patients with myositis. Clinical, immunological characteristics and the role of the anti-p155/140 antibody].

Authors:  Zsuzsanna Szankai; Melinda Nagy-Vincze; Levente Bodoki; András Jakab; Zoe Betteridge; Katalin Dankó
Journal:  Orv Hetil       Date:  2014-09-07       Impact factor: 0.540

7.  [Update: dermatomyositis].

Authors:  B Volc-Platzer
Journal:  Hautarzt       Date:  2010-01       Impact factor: 0.751

8.  Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis.

Authors:  Z E Betteridge; H Gunawardena; H Chinoy; J North; W E R Ollier; R G Cooper; N J McHugh
Journal:  Ann Rheum Dis       Date:  2008-10-17       Impact factor: 19.103

9.  Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.

Authors:  Sarah L Tansley; Zoe E Betteridge; Harsha Gunawardena; Thomas S Jacques; Catherine M Owens; Clarissa Pilkington; Katie Arnold; Shireena Yasin; Elena Moraitis; Lucy R Wedderburn; Neil J McHugh
Journal:  Arthritis Res Ther       Date:  2014-07-02       Impact factor: 5.156

Review 10.  The diagnostic utility of autoantibodies in adult and juvenile myositis.

Authors:  Sarah L Tansley; Zoe E Betteridge; Neil J McHugh
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.